Momenta Phama (NASDAQ: MNTA) announced that its novel oncology candidate, necuparanib (formerly M402), has received Orphan Drug Designation from the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE